Multiple well-established therapies are currently available to treat ulcerative colitis (UC) in Europe. TNF-α inhibitors such as Janssen / Merck’s Remicade and AbbVie / Eisai’s Humira helped to advance UC treatment, particularly for the moderate to severe population, and are now well entrenched as first-line biologics. However, over the past three years, the UC treatment landscape in Europe has seen the approval of the first non-TNF biologic (Takeda’s Entyvio), the first targeted oral therapy for UC (Pfizer’s Xeljanz), and the launch of biosimilar infliximab and adalimumab (Celltrion’s Remsima and Amgen’s Amgevita, respectively). Entyvio, a CAM-inhibitor, and Xeljanz, a Jak-inhibitor, offer alternative mechanisms of action for TNF-α refractory patients, expanding the treatment armamentarium. The availability of biosimilars has influenced physicians’ prescribing behavior and will continue to impact the UC treatment landscape.

Questions Answered:

  • What drug classes are the patient-share leaders across different lines of therapy? How are different agents positioned in surveyed physicians’ treatment algorithm?
  • What are the most influential drivers for treatment selection?
  • What are the common treatment scenarios before initiating different targeted therapies (i.e., Remicade, Humira, Simponi, Entivyo Entyvio, Xeljanz, and biosimilars)? What is the course of action upon discontinuing these agents?
  • What factors drive therapy discontinuation and switch? What factors have/will drive recent/anticipated prescribing changes?

Markets covered: France, Germany, Italy, Spain, and United Kingdom

Primary research: 250 gastroenterologists completed the survey. Of that total, 50 respondents were in France, 50 in Germany, 50 in Italy, 50 in Spain, and 50 in the United Kingdom. The survey was fielded from June 18 to July 14, 2019.

Key companies: Merck & Co., Celltrion, Hospira, Biogen, AbbVie / Eisai, Biogen, Amgen, Sandoz, Takeda, Pfizer, others

Key drugs: adalimumab (Humira and biosimilars), Entyvio, infliximab (Remicade and biosimilars), Simponi, Xeljanz

Product Description: Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Table of contents

  • Detailed, Expanded Analysis (EU5)
    • Current Treatment | Physician Insights | Ulcerative Colitis EU5 | September 2019

Author(s): Maria Genco, Ph.D

Maria Genco, is an analyst on the Immune and Inflammatory Disorders group at Decision Resources Group, primarily focusing on rheumatoid arthritis and axial spondyloarthritis. She has authored market research reports on the RA disease landscape and commercial outlook of drugs, unmet needs in RA, and market access and reimbursement for RA targeted therapies. Prior to joining Decision Resources, Dr. Genco received her and in neuroscience from Brandeis University and a in neuroscience from Wellesley College.


Related Reports

Ulcerative Colitis | Landscape & Forecast | Disease Landscape & Forecast

The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The entry of first-in-UC oral...

View Details

Ulcerative Colitis | Access & Reimbursement | Detailed, Expanded Analysis (US)

TNF-α inhibitors are well entrenched in the U.S. ulcerative colitis (UC) and Crohn’s disease (

View Details

Ulcerative Colitis | Emerging Therapies | Xeljanz (Ulcerative Colitis) Launch Tracking Wave 3

Pfizer’s Xeljanz is the first-in-class Jak inhibitor approved for ulcerative colitis (UC) in the United S...

View Details

Ulcerative Colitis | Unmet Need | Detailed, Expanded Analysis (US & EU)

MARKET OUTLOOK The moderate to severe ulcerative colitis (UC) therapy market still offers substantial opportunity for companies that can address the remaining unmet need...

View Details